Pipeline
Zyvran Pharmaceutical Inc.
ZYN 001 – P564X
Indication: Premature Ejaculation (PE)
Premature Ejaculation affects 20-30% of all men, yet no drug has been FDA approved for this. To improve and maximize the quality of life of thousands in the world, Zyvran introduces a new combination drug - P564X for treating this condition
ZYN 002 – V1007X
Indication: Dementia with Lewy Bodies (DLB)/Alzheimer’s Disease (AD)
Alzheimer’s Disease is the most common type of Dementia and constitutes about 60-70% of all dementia Cases. It severely impacts the quality of life of those diagnosed and is a significant burden for their caregivers. Zyvran introduces a mew combination drug - V1007X for treating this condition.
ZYN 003 – Z978X
Indication: Treatment-Resistant Depression (TRD)
Neuropathic pain affects 50% of people living with diabetes. 537 million persons are known to live with diabetes. Neuropathic and mixed pain states are from spinal cord trauma. These include conditions like post spinal surgery syndrome, chemotherapy-induced neuropathy and diabetic induced peripheral neuropathy. Zyvran introduces a new combination drug -- A2121X for treating this condition.
ZYN 004 – A2121X
Indication: Mixed Pain States
Neuropathic pain affects 50% of people living with diabetes. 537 million persons are known to live with diabetes. Neuropathic and mixed pain states are from spinal cord trauma. These include conditions like post spinal surgery syndrome, chemotherapy-induced neuropathy and diabetic induced peripheral neuropathy. The market need for medication for neuropathic pain is projected to be $6.3 billion in 2019. This amount is projected to further increase to $9.8 billion by 2027 at a CAGR of 5.5%. Zyvran introduces a new combination drug -- A2121X for treating this condition.